{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T05:46:24Z","timestamp":1770529584911,"version":"3.49.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The use of diuretics is extremely common in infants cared for in neonatal wards, despite the lack of proven efficacy for many conditions. The main objective of this study was to assess the rate of diuretics exposure in a multicenter French cohort. The secondary objectives were to describe the evolution of this exposure over time, the indications, the prescription practices, and the exposure rates among centers.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> An observational study was conducted in 40 Level 3 French neonatal intensive care units using the same computerized order-entry system. Neonates hospitalized between January 2017 to December 2021 with a corrected age between 24 and 44\u00a0weeks of gestation at admission were eligible.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 86,032 patients were included. The exposure rate was 8.5%, more specifically 29.4% for children born at &amp;lt; 32\u00a0weeks of gestation and 3.7% for neonates born at term. There was no significant variation over the study period, but the exposure ranged from 2.4% to 26.5% depending on the center. The main drugs prescribed were furosemide, spironolactone and dopamine with a diuretic purpose. The main indications were \u201cfluid retention,\u201d and to a lesser extent \u201cbronchopulmonary dysplasia\u201d and \u201cpost-transfusion.\u201d For furosemide, the first exposure occurred in mean at 16.5 (\u00b117.8) days of life, mean duration of exposure was 6.2 (\u00b19.5) days, and the cumulative dose was in mean 10.7 (23.9) mg\/kg.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Diuretic prescription practices vary between centers. The administration of these drugs is often non-evidence based, doses and duration of treatment easily exceed toxic thresholds.<\/jats:p>","DOI":"10.3389\/fphar.2024.1358761","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T04:56:18Z","timestamp":1710305778000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Diuretic drug utilization in neonates: a French prescription database analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Silvia","family":"Iacobelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Lorrain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezira","family":"Rabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Gouyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Bernard","family":"Gouyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bonsante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jpeds.2020.10.073","article-title":"Loop diuretics in severe bronchopulmonary dysplasia: cumulative use and associations with mortality and age at discharge","volume":"231","author":"Bamat","year":"2021","journal-title":"J. Pediatr."},{"key":"B2","unstructured":"List of maternity wards in France. Directorate of research, studies, evaluation and statistics (DREES)2023"},{"key":"B3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1442-200X.2009.02886.x","article-title":"Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants","volume":"52","author":"Gimpel","year":"2010","journal-title":"Pediatr. Int."},{"key":"B4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40264-015-0288-6","article-title":"Drug-induced renal damage in preterm neonates: state of the art and methods for early detection","volume":"38","author":"Girardi","year":"2015","journal-title":"Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0222667","DOI":"10.1371\/journal.pone.0222667","article-title":"Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research","volume":"14","author":"Gouyon","year":"2019","journal-title":"PLoS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/ppul.24592","article-title":"Respiratory medication use in extremely premature (<29 weeks) infants during initial NICU hospitalization: results from the prematurity and respiratory outcomes program","volume":"55","author":"Greenberg","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jpeds.2018.11.043","article-title":"Furosemide exposure and prevention of bronchopulmonary dysplasia in premature infants","volume":"208","author":"Greenberg","year":"2019","journal-title":"J. Pediatr."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1007\/s00467-021-04921-3","article-title":"Use of diuretics in the neonatal period","volume":"36","author":"Guignard","year":"2021","journal-title":"Pediatr. Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/jp.2011.11","article-title":"Diuretics for very low birth weight infants in the first 28 days: a survey of the U.S. neonatologists","volume":"31","author":"Hagadorn","year":"2011","journal-title":"J. Perinatol."},{"key":"B10","volume-title":"Homologous red blood cell transfusions: products, indications, alternatives","year":"2023"},{"key":"B11","volume-title":"Diuretics in neonatology: a narrative review and update","author":"Iacobelli","year":"2023"},{"key":"B12","article-title":"Furosemide","volume-title":"StatPearls treasure island (FL)","author":"Khan","year":"2023"},{"key":"B13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/jcpt.12440","article-title":"Review of drug utilization patterns in NICUs worldwide","volume":"41","author":"Krzy\u017caniak","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1055\/s-0034-1373845","article-title":"Diuretic exposure in premature infants from 1997 to 2011","volume":"32","author":"Laughon","year":"2015","journal-title":"Am. J. Perinatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13052-020-00851-2","article-title":"Furosemide use in Italian neonatal intensive care units: a national survey","volume":"46","author":"Manfredini","year":"2020","journal-title":"Ital. J. Pediatr."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ph6091094","article-title":"Clinical Pharmacology of furosemide in neonates: a review","volume":"6","author":"Pacifici","year":"2013","journal-title":"Pharm. (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.clp.2011.12.007","article-title":"Neonatal diuretic therapy: furosemide, thiazides, and spironolactone","volume":"39","author":"Segar","year":"2012","journal-title":"Clin. Perinatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1542\/peds.2012-1835","article-title":"Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia","volume":"131","author":"Slaughter","year":"2013","journal-title":"Pediatrics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12098-014-1585-2","article-title":"The Pediatrix BabySteps\u00ae Data Warehouse--a unique national resource for improving outcomes for neonates","volume":"82","author":"Spitzer","year":"2015","journal-title":"Indian J. Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2147\/TCRM.S369737","article-title":"Cumulative doses predict the risk of furosemide-induced electrolyte abnormalities in critically ill neonates","volume":"18","author":"Sridharan","year":"2022","journal-title":"Ther. Clin. Risk Manag."},{"key":"B21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpeds.2021.08.075","article-title":"Medication use in the neonatal intensive care unit and changes from 2010 to 2018","volume":"240","author":"Stark","year":"2022","journal-title":"J. Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"CD001453","DOI":"10.1002\/14651858.CD001453","article-title":"Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease","volume":"2011","author":"Stewart","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"CD001817","DOI":"10.1002\/14651858.CD001817","article-title":"Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease","volume":"2011","author":"Stewart","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/jpc.14877","article-title":"Diuretic use in infants with developing or established chronic lung disease: a practice looking for evidence","volume":"56","author":"Tan","year":"2020","journal-title":"J. Paediatr. Child. Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.earlhumdev.2018.08.009","article-title":"Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants","volume":"125","author":"Wang","year":"2018","journal-title":"Early Hum. Dev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1358761\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T04:56:21Z","timestamp":1710305781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1358761\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,13]]},"references-count":25,"alternative-id":["10.3389\/fphar.2024.1358761"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1358761","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,13]]},"article-number":"1358761"}}